Reata Pharmaceuticals Inc.’s Part 2 portion of the MOXIe Phase 2 trial of omaveloxolone in patients with Friedreich’s ataxia (FA) met the primary endpoint of change in the modified Friedreich’s Ataxia Rating Scale relative to placebo after 48 weeks of treatment.
Harpreet Singh was named CEO of Immatics Biotechnologies GmbH, a clinical-stage biopharmaceutical company active in the discovery and development of T-cell redirecting cancer immunotherapies.
Clinical-stage biopharmaceutical company Gemphire Therapeutics Inc. and privately held clinical-stage biotechnology company NeuroBo Pharmaceuticals Inc. jointly announced a definitive agreement whereby NeuroBo will merge with a wholly owned subsidiary of Gemphire in an all-stock transaction.
While Boston tends to get the lion’s share of recognition as the premier biopharma hub on the East Coast of the United States, other cities and states are looking to make their names known as a strong location for the industry. New Jersey, New York and New Hampshire have gone to great lengths to distinguish themselves, but so too has smaller Rhode Island.
Cryoport Inc. and EVERSANA announced a strategic alliance to further create a fully integrated regenerative medicine supply chain solution.
Lyndra Therapeutics and Gilead Sciences entered a partnership collaboration to develop and market ultra-long-acting oral HIV therapies.
Israel’s Pitango Venture Capital is launching a fund that will reach $150 million to invest in health technology.
The IQVIA report finds that in 2018, 27% of drugs launched were for cancer or its symptoms, and 20% were for infectious diseases.
March 2019 was a busy month for biopharma and medical device company initial public offerings.
There has been a heightened interest in longevity research. Some have noted that older billionaires such as Bill Gates, Michael Bloomberg, Richard Branson and others have been investing heavily into biopharma companies focused on aging and aging-related diseases.
